ArticlePloS one2015
Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Trial
- Paraneoplastic Intracellular Neuropathies: A Narrative Review.Neurology and therapy · 2026Review
- Onconeural antigen NOVA1 dysregulates RNA alternative splicing in breast cancer.RNA (New York, N.Y.) · 2026Article
- Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.Cell & bioscience · 2024Review
- Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.European journal of neurology · 2024Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer.Molecular cancer · 2024Review
- Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer.Science translational medicine · 2023Article
- Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1.Annals of neurology · 2022Article
- Beneficial autoimmunity improves cancer prognosis.Nature reviews. Clinical oncology · 2021Review
- [Immunotherapy Advances in Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer.Translational cancer research · 2020Article
- Chemo-immunotherapy as first-line treatment for small-cell lung cancer.Therapeutic advances in medical oncology · 2020Review
- Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.Nature reviews. Clinical oncology · 2019Review
- Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.Neurology · 2019Article
- Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.Journal for immunotherapy of cancer · 2019Review
- Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.Thoracic cancer · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFavourable small cell lung carcinoma (SCLC) survival outcomes have been reported in patients with paraneoplastic neurological disorders (PNDs) associated with neuronal antibodies (Neur-Abs), but the presence of a PND might have expedited diagnosis. Our aim was to establish whether neuronal antibodies, independent of clinical neurological features, correlate with SCLC survival. EXPERIMENTAL
design262 consecutive SCLC patients were examined: of these, 24 with neurological disease were excluded from this study. The remaining 238 were tested for a broad array of Neur-Abs at the time of cancer diagnosis; survival time was established from follow-up clinical data.
resultsMedian survival of the non-PND cohort (n = 238) was 9.5 months. 103 patients (43%) had one or more antigen-defined Neur-Abs. We found significantly longer median survival in 23 patients (10%) with HuD/anti-neuronal nuclear antibody type 1 (ANNA-1, 13.0 months P = 0.037), but not with any of the other antigen-defined antibodies, including the PND-related SOX2 (n = 56, 24%). An additional 28 patients (12%) had uncharacterised anti-neuronal nuclear antibodies (ANNA-U); their median survival time was longer still (15.0 months, P = 0.0048), contrasting with the survival time in patients with non-neuronal anti-nuclear antibodies (detected using HEp-2 cells, n = 23 (10%), 9.25 months). In multivariate analyses, both ANNA-1 and ANNA-U independently reduced the mortality hazard by a ratio of 0.532 (P = 0.01) and 0.430 (P<0.001) respectively.
conclusionsANNAs, including the newly described ANNA-U, may be key components of the SCLC immunome and have a potential role in predicting SCLC survival; screening for them could add prognostic value that is similar in magnitude to that of limited staging at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.